Gimatecan
Information
- Drug Name
- Gimatecan
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Gimatecan is a novel lipophilic camptothecin | BCL2 | BCL2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00087061 | Completed | Phase 1/Phase 2 | Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma | May 2004 | June 2005 |
| NCT00410358 | Completed | Phase 1 | A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor. | June 2006 | |
| NCT00420485 | Completed | Phase 1 | Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors | March 2006 | November 2010 |
| NCT00441610 | Completed | Phase 1 | An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor | January 2007 | |
| NCT00487058 | Completed | Phase 1 | A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors | May 2007 | |
| NCT00493571 | Completed | Phase 1 | Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes | August 2007 | May 2014 |
| NCT04501029 | Unknown status | Phase 2 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | October 1, 2020 | October 1, 2023 |
| NCT04571489 | Unknown status | Phase 2 | A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer | December 1, 2020 | December 1, 2023 |
| NCT04846842 | Unknown status | Phase 2 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | July 1, 2021 | July 1, 2023 |